Sanofi's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Sanofi in the fourth quarter 2025?
Sanofi achieved a return on average equity (ROE) of 10.82 % in its fourth quarter 2025, this is above SNY's average return on equity of 9.76%.
Sanofis equity during the 12 months ending in the fourth quarter 2025 are valued at $81 billion

ROE has advanced compared to 7.83% in the third quarter 2025, due to net income growth.

Within the Major Pharmaceutical Preparations industry 57 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 1340, from total ROE ranking in the third quarter 2025 at 1686.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Equity Change	4.43 %	-7.9 %	-7.9 %	-7.9 %	-
Y / Y Net Income Change	39.75 %	-	-	-	3.35 %
Net Income (TTM) in Millions	8,793	6,292	6,292	6,292	6,292
Return On Equity (TTM)	10.82 %	7.83 %	7.66 %	7.51 %	7.36 %
SNY's Total Ranking	# 1340	# 1686	#	#	#
Equity (TTM) in Millions	84,159	80,315	80,315	80,315	80,590
Seq. Equity Change	4.79 %	0 %	0 %	-0.34 %	-7.58 %
Seq. Net Income Change	-	-	-	-	-

Back to SNY Management Effectiveness >> SNY's 5 Years Annual ROE >> Compare SNY ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 58
Sector	# 149
Overall	# 1340

Return On Equity Statistics
High	Average	Low
19.56 %	9.76 %	4.8 %
(Dec 31 2020)		(Dec 31 2019)

SNY Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	84,159	80,590	82,249	80,398	78,129
Y / Y Equity Change	4.43 %	-2.02 %	2.3 %	2.9 %	1.17 %
Net Income in Millions	8,877	6,079	5,880	8,937	7,428
Y / Y Net Income Change	46.03 %	3.38 %	-34.21 %	20.31 %	-47.29 %
Return On Equity	10.55 %	7.54 %	7.15 %	11.12 %	9.51 %

Back to SNY Management Effectiveness >> SNY's 5 Years Annual ROE >> Compare SNY ROE to its Competitors

Annual Roe Comment

In 2025 ROE improved to 10.55 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
SNY's' Return on Equity at Yahoo Finance
SNY's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for SNY's Competitors
Subscribers only: Roe for Sanofi's Suppliers
Subscribers only: Return On Equity for SNY's Customers

Companies with similar Return On Equity at Dec 31 2025, within Healthcare Sector	ROE
Incyte Corporation	29.15 %
Waters Corporation	28.52 %
Puma Biotechnology Inc	27.81 %
Resmed Inc	25.18 %
Encompass Health Corporation	24.76 %
Prestige Consumer Healthcare Inc	24.66 %
Catalyst Pharmaceuticals Inc	24.32 %
Collegium Pharmaceutical Inc	24.11 %
Xoma Royalty Corporation	23.97 %
Chemed Corporation	23.92 %
Iradimed Corporation	23.83 %
Lifevantage Corp	23.04 %
Hims and Hers Health Inc	22.99 %
Vertex Pharmaceuticals Inc	22.70 %
Pacs Group Inc	22.54 %
Spero Therapeutics Inc	22.53 %
Iqvia Holdings Inc	22.05 %
Ge Healthcare Technologies Inc	21.90 %
Msa Safety Inc	21.82 %
Mimedx Group Inc	21.24 %
Universal Health Services Inc	21.19 %
Inspire Medical Systems inc	21.07 %
Astrazeneca Plc	21.00 %
Haemonetics Corporation	20.80 %
Sbc Medical Group Holdings Incorporated	20.79 %
Lantheus Holdings Inc	20.58 %
Electromed Inc	20.54 %
Teva Pharmaceutical Industries Limited	20.07 %
Harmony Biosciences Holdings inc	19.84 %
Pediatrix Medical Group Inc	19.58 %

Date modified: 2026-06-24T10:07:58+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.